Clinical Trials Logo

Leukemia clinical trials

View clinical trials related to Leukemia.

Filter by:

NCT ID: NCT05541224 Completed - Clinical trials for Acute Myeloid Leukemia

A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic Markers

Start date: November 1, 2019
Phase:
Study type: Observational

This is a retrospective, translational, epidemiologic, multicenter, non-interventional study (No EPA study) to provide insights into disease epidemiology, disease biology, treatment regimens, and clinical outcomes of patients with acute myeloblastic leukemia (AML) in routine clinical practice according to their molecular markers. The primary objective of the study is to describe the use of the main molecular markers (FLT3 and NPM1) in the real-life according of the type of AML, treating institution, patients' characteristics, and disease status.

NCT ID: NCT05518357 Completed - Clinical trials for Relapsed/Refractory Acute Myeloid Leukemia

LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Start date: June 24, 2022
Phase: Phase 1
Study type: Interventional

This is a single-center, single-arm, open-label phase I clinical study to determine the safety and efficacy of LILRB4 STAR-T cells in relapsed/refractory acute myeloid leukemia subjects.

NCT ID: NCT05488613 Completed - Clinical trials for Acute Myeloid Leukemia (AML)

Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)

Start date: September 24, 2020
Phase:
Study type: Observational

This was a non-interventional, retrospective registry study, utilizing electronic health record (EHR) data collected in the hospital district of Helsinki and Uusimaa (HUS). Real-world health care resource utilization (HCRU) of AML patients was characterized.

NCT ID: NCT05476562 Completed - Clinical trials for Chronic Myeloid Leukemia

Study Conducted Among Patients With CML

Start date: March 8, 2021
Phase:
Study type: Observational

Retrospective, non-interventional observational cohort study conducted among patients with CML.

NCT ID: NCT05456048 Completed - Clinical trials for Refractory Acute Myeloid Leukemia

Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML

Start date: December 3, 2018
Phase:
Study type: Observational

The aim of this study is to reveal the influence of gene mutations on the treatment response of the regimen of HHT combined with Venetoclax plus AZA versus venetoclax plus HMA in the salvage therapy of RR-AML.

NCT ID: NCT05455268 Completed - Clinical trials for Pediatric Acute Myeloid Leukemia

Information Support Using an Online Learning Platform for Malaysian Pediatric Leukemia and Lymphoma Parents

eHOPE
Start date: July 15, 2022
Phase: N/A
Study type: Interventional

This is a study protocol to determine whether it is feasible to support parents of children with blood cancers by providing information over an online learning platform. This study will be conducted in Malaysia. An online learning platform will be used to provide information relevant to parents who care for children diagnosed with leukemia or lymphoma. The use of this platform will be compared with current usual care, where only verbal discussions and ad hoc caregiver training is provided to support these parents, based on the clinician's judgement. Participants knowledge and confidence level in caregiving as well as coping will be compared between the two groups. To determine the feasibility of this method of information support, the researchers will also obtain feedback from participants who used the online learning platform and determine whether there are many who drop out from using it. The findings will determine whether use of online learning platform is suitable to deliver information support for parents, in view of currently limited resources for supportive care in childhood cancer care in Malaysia.

NCT ID: NCT05433532 Completed - Clinical trials for Acute Myeloid Leukemia

Study of Azacitidine,Venetoclax,and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients

Start date: May 1, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of azacitidine,venetoclax,and flumatinib in newly diagnosed Philadelphia chromosome-positive acute leukemia and accelerated phase or blast phase chronic myeloid leukemia patients.

NCT ID: NCT05421091 Completed - Clinical trials for Chronic Myeloid Leukemia

Special Drug Use-results Surveillance of Scemblix Tablets

Start date: July 4, 2022
Phase:
Study type: Observational

Uncontrolled, central registration system, all-case, multicenter, special drug use-results surveillance.

NCT ID: NCT05387330 Completed - Clinical trials for Chronic Myeloid Leukemia

Dynamic Changes in the Levels of sCD62L and SPARC in Chronic Myeloid Leukemia Patients During Imatinib Treatment

Start date: April 1, 2018
Phase:
Study type: Observational

This study aims to monitor the levels of soluble L-selectin (sCD62L) and secreted protein acidic rich in cysteine (SPARC) in chronic phase chronic myeloid leukemia (CP-CML) patients at baseline and after three and six months of imatinib therapy and evaluated the effect of imatinib on their levels and correlated their levels to clinical and laboratory parameters.

NCT ID: NCT05286528 Completed - Clinical trials for Chronic Myeloid Leukaemia

Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

Start date: November 18, 2020
Phase:
Study type: Observational

The objectives of this study are to describe patient demographics, clinical and disease characteristics and treatment patterns of Chronic Lymphoid Leukaemia (CML) in Hungary. The primary endpoint of this study is the overall survival of CML patients treated with tyrosine kinase inhibitors in Hungary. The Overall Survival (OS) of all enrolled patients, OS by sequence pattern and by the number of treatment lines will be analyzed. Secondary objectives are description of the treatment length in 1st and later lines, incidence and prevalence of CML, the patient demographics (as age, gender, comorbidities), average number of patients' comorbidities, most frequent comorbidities and patient number with comorbidities at baseline and at different treatment lines by investigated Thyrosine Kinase Inhibitor (TKI), distribution of the investigated TKI therapies by treatment lines